Tralokinumab 治疗严重特应性皮炎® 在实际临床实践中的首个短期有效性和安全性数据。

IF 4 3区医学 Q1 DERMATOLOGY

Dermatitis Pub Date : 2024-05-01 Epub Date: 2023-05-02 DOI:10.1089/derm.2023.0030

Rubén García Castro, Felipe Heras Mendaza, Diana Inmaculada Santiago Sánchez-Mateos, María Carmen Fariña Sabrís, Inmaculada Alcaraz León

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

First Short-Term Effectiveness and Security Data of Tralokinumab in Severe Atopic Dermatitis® in Real Clinical Practice.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Dermatitis 医学-皮肤病学

CiteScore

5.30

自引率

11.50%

发文量

251

审稿时长

>12 weeks

期刊介绍： Dermatitis is owned by the American Contact Dermatitis Society and is the home journal of 4 other organizations, namely Societa Italiana di Dermatologica Allergologica Professionale e Ambientale, Experimental Contact Dermatitis Research Group, International Contact Dermatitis Research Group, and North American Contact Dermatitis Group. Dermatitis focuses on contact, atopic, occupational, and drug dermatitis, and welcomes manuscript submissions in these fields, with emphasis on reviews, studies, reports, and letters. Annual sections include Contact Allergen of the Year and Contact Allergen Alternatives, for which papers are chosen or invited by the respective section editor. Other sections unique to the journal are Pearls & Zebras, Product Allergen Watch, and news, features, or meeting abstracts from participating organizations.